Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svane

Showing results (741-750 of 811) with videos related to

Pageof 82
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced MelanomaJoachim S Granhøj, Sigrid M H Mannering, Kasper Madsen, et al.
Nature Biotechnology|August 30, 2016
Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodesAmalie Kai Bentzen, Andrea Marion Marquard, Rikke Lyngaa, et al.
Nature Immunology|March 4, 2020
Author Correction: Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1Michael D Crowther, Garry Dolton, Mateusz Legut, et al.
Cancers|November 17, 2020
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8<sup>+</sup> T Cells in Non-Melanoma Cancers Compared to MelanomaAishwarya Gokuldass, Arianna Draghi, Krisztian Papp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2022
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)Inna M Chen, Julia S Johansen, Susann Theile, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Nature Immunology|January 22, 2020
Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1Michael D Crowther, Garry Dolton, Mateusz Legut, et al.
International Journal of Obesity (2005)|April 23, 2020
Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomyAleksander Eiken, Stefan Fuglsang, Markus Eiken, et al.
Nature Medicine|June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Metabolism: Clinical and Experimental|March 12, 2025
Fat absorption and metabolism after Roux-en-Y gastric bypass surgeryMorten Hindsø, Annemarie Lundsgaard, Bojan Marinkovic, et al.
Pageof 82

Showing results (741-750 of 811) with videos related to

Sort By:
Pageof 82
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced MelanomaJoachim S Granhøj, Sigrid M H Mannering, Kasper Madsen, et al.
Nature Biotechnology|August 30, 2016
Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodesAmalie Kai Bentzen, Andrea Marion Marquard, Rikke Lyngaa, et al.
Nature Immunology|March 4, 2020
Author Correction: Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1Michael D Crowther, Garry Dolton, Mateusz Legut, et al.
Cancers|November 17, 2020
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8<sup>+</sup> T Cells in Non-Melanoma Cancers Compared to MelanomaAishwarya Gokuldass, Arianna Draghi, Krisztian Papp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2022
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)Inna M Chen, Julia S Johansen, Susann Theile, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, et al.
Nature Immunology|January 22, 2020
Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1Michael D Crowther, Garry Dolton, Mateusz Legut, et al.
International Journal of Obesity (2005)|April 23, 2020
Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomyAleksander Eiken, Stefan Fuglsang, Markus Eiken, et al.
Nature Medicine|June 8, 2019
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo Antonio Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, et al.
Metabolism: Clinical and Experimental|March 12, 2025
Fat absorption and metabolism after Roux-en-Y gastric bypass surgeryMorten Hindsø, Annemarie Lundsgaard, Bojan Marinkovic, et al.
Pageof 82